Market Cap 13.81M
Revenue (ttm) 2.07M
Net Income (ttm) -3.53M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -170.53%
Debt to Equity Ratio 0.00
Volume 55,500
Avg Vol 5,754,924
Day's Range N/A - N/A
Shares Out 4.33M
Stochastic %K 46%
Beta 1.80
Analysts Strong Buy
Price Target $8.00

Company Profile

Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 327 8778
Address:
245 First Street, Riverview II, 18th Floor, Cambridge, United States
shock89
shock89 May. 11 at 2:12 PM
0 · Reply
SuperGreenToday
SuperGreenToday May. 11 at 10:33 AM
0 · Reply
shock89
shock89 May. 9 at 12:16 AM
$LRHC Hope we can get 10k and DA soon! Then it will squeeze like $UGRO $SKK $CYCN
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 6 at 4:08 AM
$CYCN RSI: 56.98, MACD: 0.1922 Vol: 0.14, MA20: 3.07, MA50: 2.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 2:33 AM
$CYCN Current Stock Price: $3.26
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 4:03 PM
$CELZ : Momentum Building as Breakthrough Data Fuels Renewed Interest 🧬 Creative Medical Technology Holdings is gaining attention after its April 28 breakthrough, reporting a 93% response rate in its Ultrasome knee osteoarthritis program. Strong clinical results combined with improving price action are starting to bring momentum back to the story. Technical View: 🔸 Tight consolidation with buyers stepping in on dips 🔸 Higher lows forming, showing strength 🔸 Price compressing beneath resistance Key Levels to Watch: 📈 $2.02 🟰 Key support 📈 $2.21–$2.51 🟰 Current consolidation range 📈 $2.74 🟰 Breakout level 📈 $3.08–$3.34 🟰 Major resistance zone 📈 $3.86 🟰 High timeframe resistance With strong clinical momentum and multiple catalysts ahead, CELZ is targeting $100B+ markets, positioning itself for increased attention as the story continues to unfold. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $CYCN $DYAI $MBRX $AIXC
1 · Reply
Bullbear1010101
Bullbear1010101 May. 1 at 1:19 AM
$CYCN Guess i dont want to search .. but anyone know if insiders sold 7-8 on that pump
0 · Reply
FonsieTrader
FonsieTrader Apr. 29 at 9:44 PM
$CYCN 👀 Quietly setting up again. After the spike → consolidation holding above $2.80–$3.00. No panic selling, structure staying tight. TTM Squeeze cooling off → reset phase. MFI recovering → buyers stepping back in. If this reclaims $3.40–$3.50 with volume… this can push for another leg. Not dead. Just loading.
1 · Reply
FonsieTrader
FonsieTrader Apr. 29 at 9:41 PM
$CYCN 👀 Quietly setting up again. After the spike → consolidation holding above $2.80–$3.00. No panic selling, structure staying tight. TTM Squeeze cooling off → reset phase. MFI recovering → buyers stepping back in. If this reclaims $3.40–$3.50 with volume… this can push for another leg. Not dead. Just loading.
0 · Reply
Oscarthesuperstar1
Oscarthesuperstar1 Apr. 29 at 2:46 PM
$CYCN Bottom could be in, making this a very attractive price and time to buy
0 · Reply
Latest News on CYCN
Cyclerion Therapeutics files $25M mixed securities shelf

2025-02-04T21:45:08.000Z - 1 year ago

Cyclerion Therapeutics files $25M mixed securities shelf


Biotech Alert: Searches spiking for these stocks today

2024-11-18T15:55:13.000Z - 1 year ago

Biotech Alert: Searches spiking for these stocks today

TFFP


Cyclerion Therapeutics appoints Regina Graul as CEO

2024-08-07T11:26:09.000Z - 1 year ago

Cyclerion Therapeutics appoints Regina Graul as CEO


Regina Graul, Ph.D., Promoted to Chief Executive Officer

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer


Cyclerion Therapeutics appoints Graul as President

2023-12-04T13:04:15.000Z - 2 years ago

Cyclerion Therapeutics appoints Graul as President


Cyclerion Appoints Regina Graul, Ph.D., as President

Dec 4, 2023, 8:00 AM EST - 2 years ago

Cyclerion Appoints Regina Graul, Ph.D., as President


Cyclerion Announces Reverse Stock Split

May 15, 2023, 1:00 PM EDT - 3 years ago

Cyclerion Announces Reverse Stock Split


Cyclerion Therapeutics to Host Pipeline Update Webinar

Apr 20, 2021, 7:00 AM EDT - 5 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar


shock89
shock89 May. 11 at 2:12 PM
0 · Reply
SuperGreenToday
SuperGreenToday May. 11 at 10:33 AM
0 · Reply
shock89
shock89 May. 9 at 12:16 AM
$LRHC Hope we can get 10k and DA soon! Then it will squeeze like $UGRO $SKK $CYCN
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 6 at 4:08 AM
$CYCN RSI: 56.98, MACD: 0.1922 Vol: 0.14, MA20: 3.07, MA50: 2.39 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
BillionerOfKing
BillionerOfKing May. 5 at 2:33 AM
$CYCN Current Stock Price: $3.26
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy May. 4 at 4:03 PM
$CELZ : Momentum Building as Breakthrough Data Fuels Renewed Interest 🧬 Creative Medical Technology Holdings is gaining attention after its April 28 breakthrough, reporting a 93% response rate in its Ultrasome knee osteoarthritis program. Strong clinical results combined with improving price action are starting to bring momentum back to the story. Technical View: 🔸 Tight consolidation with buyers stepping in on dips 🔸 Higher lows forming, showing strength 🔸 Price compressing beneath resistance Key Levels to Watch: 📈 $2.02 🟰 Key support 📈 $2.21–$2.51 🟰 Current consolidation range 📈 $2.74 🟰 Breakout level 📈 $3.08–$3.34 🟰 Major resistance zone 📈 $3.86 🟰 High timeframe resistance With strong clinical momentum and multiple catalysts ahead, CELZ is targeting $100B+ markets, positioning itself for increased attention as the story continues to unfold. Communicated Disclaimer: https://tinyurl.com/TherealshortsqueezyCELZ1 Sector Peers: $CYCN $DYAI $MBRX $AIXC
1 · Reply
Bullbear1010101
Bullbear1010101 May. 1 at 1:19 AM
$CYCN Guess i dont want to search .. but anyone know if insiders sold 7-8 on that pump
0 · Reply
FonsieTrader
FonsieTrader Apr. 29 at 9:44 PM
$CYCN 👀 Quietly setting up again. After the spike → consolidation holding above $2.80–$3.00. No panic selling, structure staying tight. TTM Squeeze cooling off → reset phase. MFI recovering → buyers stepping back in. If this reclaims $3.40–$3.50 with volume… this can push for another leg. Not dead. Just loading.
1 · Reply
FonsieTrader
FonsieTrader Apr. 29 at 9:41 PM
$CYCN 👀 Quietly setting up again. After the spike → consolidation holding above $2.80–$3.00. No panic selling, structure staying tight. TTM Squeeze cooling off → reset phase. MFI recovering → buyers stepping back in. If this reclaims $3.40–$3.50 with volume… this can push for another leg. Not dead. Just loading.
0 · Reply
Oscarthesuperstar1
Oscarthesuperstar1 Apr. 29 at 2:46 PM
$CYCN Bottom could be in, making this a very attractive price and time to buy
0 · Reply
Lifefinder
Lifefinder Apr. 28 at 7:45 PM
$CYCN I think we have a winner
1 · Reply
Lifefinder
Lifefinder Apr. 28 at 5:44 PM
$CYCN maybe today
0 · Reply
ShortTheStock
ShortTheStock Apr. 26 at 8:39 AM
$CYCN short it lovely
1 · Reply
EZYME22
EZYME22 Apr. 24 at 12:55 AM
$CYCN what thesis remains here? gotta be a pump coming?
2 · Reply
Whitewasabi
Whitewasabi Apr. 23 at 7:12 PM
$CYCN this will probably pump soon
0 · Reply
TheZymeth
TheZymeth Apr. 22 at 7:39 PM
$CYCN time to accumulate while this is silent! 🤫
0 · Reply
EdwardTeach
EdwardTeach Apr. 22 at 5:10 PM
2 · Reply
EdwardTeach
EdwardTeach Apr. 22 at 1:57 PM
0 · Reply
StockTwitsGhost
StockTwitsGhost Apr. 20 at 5:12 PM
$CYCN Those buying clearly have not read today’s S-4 filing. And if they have then they don’t understand what they read. 🤷🏼‍♀️🤦‍♂️
0 · Reply
StockTwitsGhost
StockTwitsGhost Apr. 20 at 1:01 PM
$CYCN The April 17 amendment is a structured surrender that forces CYCN shareholders to bankroll the company's own liquidation. By tightening the "Net Cash" definition, every dollar of legacy debt or severance now directly erodes the tiny 1.5% ownership stake. Furthermore, the $380 million in new capital is strictly walled off; current shareholders must absorb 100% of the "cleanup" costs of the old business, while the CVR payout was burdened with new administrative deductions that make a legacy asset payday nearly impossible. You are essentially paying for the privilege of being diluted by 98.5% just to keep the ticker from hitting zero.
1 · Reply
StockTwitsGhost
StockTwitsGhost Apr. 20 at 12:57 PM
$CYCN S-4 filed today mentions an April 17 amendment functions as a final "valuation haircut" for Cyclerion shareholders. While the high-level goal remains a merger with Korsana, the fine print was tightened to protect the $380 million in new PIPE capital at your expense. Here are the key numbers from the April 17 changes: The 1.5% Ownership Cap: Your collective ownership in the new company is fixed at 1.5%, but the amendment reinforces that this is a "ceiling." If Cyclerion’s Net Cash—calculated after subtracting severance, lease exits, and legal fees—falls below the newly tightened thresholds, that 1.5% will be adjusted downward. Effectively, CYCN shareholders are footing the bill for 100% of the company’s shutdown costs. CVR "Net" Deductions: The Contingent Value Right (CVR) for legacy assets was amended to allow the combined company to deduct more administrative and "disposition" costs. Instead of receiving a clean percentage of a sale
1 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 16 at 3:30 PM
$VTGN Any good CEO already has a contingency plan in place in case data is not good. Most likely they are already in talks for some sort of strategic alt deal if the data is meh. $RLYB did it, $CYCN did it, $BRNS did it, $NEUP did it, all behind the scenes while waiting on data and continuing business as usual. With 60m cash on hand Dec 31, and likely 45m+ on hand today we are trading at over 1/2 cash value. Any binary announcement likely has limited downside and loads of upside. Again, no matter the result here I still think it is a asymmetrical risk/reward situation. Risk -30% to possibly gain 100%+ Do your own DD of course but I've loaded up the boat. Options: A). Data is good, stock pumps B). Data is bad, announce strat alt review , stock rebounds to near current levels C). Reverse merger deal out of nowhere, stock explodes based on cash position. Look at $RLYB $CYCN $BRNS etc. All of them happened out of nowhere.
2 · Reply